The central government has barred imports of medicines that have less than one year of shelf life left, a move that tightens the rules for foreign drugs entering India and gives the sector a clearer line on what can be brought into the country. The notification, issued by the Union health ministry, amends the Drugs Rules, 1945, and applies to imports of drugs and biological products that are not already covered by a different shelf life condition. The ministry said the change will help ensure that imported medicines retain enough usable life by the time they reach patients, reducing the risk of stock expiring in warehouses or on pharmacy shelves.
The medicine import rule comes at a time when India is tightening oversight of its pharmaceutical supply chain. Imports of medicines, particularly high value and specialised products, are a sensitive area because quality and expiry control directly affect patient safety. Officials have argued that a clear shelf life floor is a practical safeguard, even though it may narrow the range of stock that importers can bring in. Industry groups have also been watching the change closely, because it affects planning, procurement and the cost of holding imported stock.
How the medicine import rule changed
Under the amended rule, a drug cannot be imported into India if it has less than one year of shelf life remaining at the time of import. The one year floor applies broadly, but the notification creates a specific exception for biological drugs and radiopharmaceuticals, which are allowed to be imported with a shorter remaining life. For those products, the importer must ensure that at least 60 per cent of the shelf life remains. The distinction reflects the nature of biological products, which often have shorter total shelf lives and are produced in smaller, more specialised batches than conventional medicines.
The rule is framed as an amendment to the Drugs Rules, 1945, which govern the manufacture, sale and import of drugs in India. Importers will need to check the remaining shelf life at the point of import, rather than at the point of manufacture or dispatch. That timing matters, because shipping, customs clearance and testing can consume weeks or months. A consignment that looked compliant when it left a foreign plant could fall below the floor by the time it arrives, so importers will need to build in a margin for transit and clearance.
The notification does not, on its own, change the approval process for a drug. A product still needs the relevant import licence and must meet quality and labelling requirements. What changes is the additional shelf life test that sits alongside those requirements. For biological drugs and radiopharmaceuticals, the 60 per cent allowance gives importers more room, but it still sets a clear minimum. A biological product with only a small fraction of its shelf life left will not qualify, even if it is urgently needed.
Why the medicine import floor matters for patients
For patients, the most direct effect of the medicine import rule is on availability and safety. Medicines with very short remaining shelf life carry a higher risk of expiring before they are used, particularly if they are stocked in smaller hospitals or pharmacies that do not turn over stock quickly. A one year floor reduces that risk and gives distributors and pharmacies a longer window to sell and dispense the product. It also reduces the chance that a patient receives a medicine close to expiry, which can be a concern for drugs that require a full course of treatment.
The rule may also affect the supply of certain imported drugs, particularly those that are not made in India and are sourced in small quantities. Importers may decide not to bring in a consignment if the remaining shelf life is close to the floor, rather than risk rejection at the border. That could create short term gaps for niche products, although officials are likely to argue that the trade off is justified by the safety benefit. For widely used imported medicines, the effect is likely to be smaller, because importers can plan shipments to meet the floor.
For the health system, the change adds a predictable standard. Hospitals and procurement agencies can be more confident that imported stock will have a usable life on arrival, which helps with inventory planning. It also aligns India with the practice in several other markets, where regulators set minimum remaining shelf life requirements for imported pharmaceuticals. The clarity may help importers too, because they no longer have to guess whether a consignment with a short remaining life will be accepted.
What the medicine import change leaves unchanged
The medicine import rule does not ban imports of medicines outright, and it does not change the list of drugs that can be imported. It sets a shelf life condition, not a product ban. Drugs that meet the floor can still be imported under the existing licensing system, and biological drugs and radiopharmaceuticals retain their 60 per cent allowance. The rule also does not alter domestic manufacturing rules, which are governed separately, or the pricing controls that apply to certain essential medicines.
Importers will need to adjust their sourcing and logistics, but the core framework remains the same. They must still hold the relevant licences, comply with quality standards and follow labelling and storage rules. The shelf life test is an additional check, not a replacement for those requirements. Over time, the government may review whether the one year floor and the 60 per cent allowance strike the right balance, particularly for biological products where shelf lives are inherently shorter.
For now, the message from the notification is clear: imported medicines must arrive with enough life left to be used safely and without waste. That principle is likely to shape how importers plan shipments, how distributors manage stock, and how hospitals assess the imported drugs they rely on for patients who need treatments that are not made in India.